Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir

Fiona McPhee, Dennis Hernandez, Fei Yu, Joseph Ueland, Aaron Monikowski, Arlene Carifa, Paul Falk, Chunfu Wang, Robert Fridell, Timothy Eley, Nannan Zhou, David Gardiner – 15 March 2013 – In a sentinel cohort, hepatitis C virus (HCV) patients (primarily genotype [GT] 1a) were treated with daclatasvir (NS5A inhibitor) and asunaprevir (NS3 protease inhibitor). Preexistence, emergence, and persistence of resistance variants in patients who failed this treatment are described.

Incidence and prevalence of hepatitis C in prisons and other closed settings: Results of a systematic review and meta‐analysis

Sarah Larney, Hannah Kopinski, Curt G. Beckwith, Nickolas D. Zaller, Don Des Jarlais, Holly Hagan, Josiah D. Rich, Brenda J. Bergh, Louisa Degenhardt – 15 March 2013 – People detained in prisons and other closed settings are at elevated risk of infection with hepatitis C virus (HCV). We undertook a systematic review and meta‐analysis with the aim of determining the rate of incident HCV infection and the prevalence of anti‐HCV among detainees in closed settings. We systematically searched databases of peer‐reviewed literature and widely distributed a call for unpublished data.

Characterization of the dynamics of hepatitis B virus resistance to adefovir by ultra‐deep pyrosequencing

Christophe Rodriguez, Stéphane Chevaliez, Paul Bensadoun, Jean‐Michel Pawlotsky – 15 March 2013 – Hepatitis B virus (HBV) resistance to nucleoside/nucleotide analogs is frequent. Ultra‐deep pyrosequencing (UDPS) is a powerful new tool that can detect minor viral variants and characterize complex quasispecies mixtures. We used UDPS to analyze the dynamics of adefovir‐resistant HBV variants in patients with chronic HBV infection in whom adefovir resistance occurred during treatment. Amino acid substitutions known to confer resistance to adefovir were detected at baseline in most patients.

Faldaprevir combined with peginterferon alfa‐2a and ribavirin in chronic hepatitis C virus genotype‐1 patients with prior nonresponse: SILEN‐C2 trial

Mark S. Sulkowski, Marc Bourlière, Jean‐Pierre Bronowicki, Tarik Asselah, Jean‐Michel Pawlotsky, Stephen D. Shafran, Stanislas Pol, Stefan Mauss, Dominique Larrey, Yakov Datsenko, Jerry O. Stern, George Kukolj, Joseph Scherer, Gerhard Nehmiz, Gerhard G. Steinmann, Wulf O. Böcher – 15 March 2013 – Faldaprevir (BI 201335) is a potent, hepatitis C virus (HCV) NS3/4A protease inhibitor.

Incidence and prevalence of hepatitis C in prisons and other closed settings: Results of a systematic review and meta‐analysis

Sarah Larney, Hannah Kopinski, Curt G. Beckwith, Nickolas D. Zaller, Don Des Jarlais, Holly Hagan, Josiah D. Rich, Brenda J. Bergh, Louisa Degenhardt – 15 March 2013 – People detained in prisons and other closed settings are at elevated risk of infection with hepatitis C virus (HCV). We undertook a systematic review and meta‐analysis with the aim of determining the rate of incident HCV infection and the prevalence of anti‐HCV among detainees in closed settings. We systematically searched databases of peer‐reviewed literature and widely distributed a call for unpublished data.

Prediction models of long‐term Cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: Risk scores integrating host and virus profiles

Mei‐Hsuan Lee, Hwai‐I. Yang, Jessica Liu, Richard Batrla‐Utermann, Chin‐Lan Jen, Uchenna H. Iloeje, Sheng‐Nan Lu, San‐Lin You, Li‐Yu Wang, Chien‐Jen Chen, R.E.V.E.A.L.‐HBV Study Group – 15 March 2013 – Integrating host and HBV characteristics, this study aimed to develop models for predicting long‐term cirrhosis and hepatocellular carcinoma (HCC) risk in chronic hepatitis B virus (HBV) patients.

High prevalence of vitamin A deficiency and vitamin D deficiency in patients evaluated for liver transplantation

Mukund Venu, Eric Martin, Kia Saeian, Samer Gawrieh – 14 March 2013 – Deficiencies in vitamins A, D, and E have been linked to night blindness, bone health, and post–liver transplant reperfusion injury. The aim of this study was to determine the prevalence and predictive factors of fat‐soluble vitamin deficiencies in liver transplant candidates. We reviewed the medical records of liver transplant candidates at our center from January 2008 to September 2011.

Development, management, and resolution of biliary complications after living and deceased donor liver transplantation: A report from the adult‐to‐adult living donor liver transplantation cohort study consortium

Michael A. Zimmerman, Talia Baker, Nathan P. Goodrich, Chris Freise, Johnny C. Hong, Sean Kumer, Peter Abt, Adrian H. Cotterell, Benjamin Samstein, James E. Everhart, Robert M. Merion – 11 March 2013 – Adult recipients of living donor liver transplantation (LDLT) have a higher incidence of biliary complications than recipients of deceased donor liver transplantation (DDLT). Our objective was to define the intensity of the interventions and the time to resolution after the diagnosis of biliary complications after liver transplantation.

Subscribe to